Skip to main content

Table 1 Pancreatic tumor incidence, multiplicity and metastasis

From: Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

Treatment

Incidence (%)

Incidence, T ≥ 500 mm3(%)

Multiplicity

Metastasis (%)

Liver met (%)

Lung met (%)

Placebo

14/14 (100%)

11/14 (78%)

27/14 = 1.9

7/14 (50%)

6/14 (43%)

3/14 (21%)

DMAPT

11/15 (73%)

8/11 (73%)

18/15 = 1.2

5/11 (45%)

2/11 (18%)

5/11 (45%)

Gemcitabine

6/14 (43%)*

2/6 (33%)

6/14 = 0.4*

3/6 (50%)

3/6 (50%)

1/6 (17%)

DMAPT/gemcitabine

9/15 (60%)*

1/9 (11%)*

10/15 = 0.7*

2/9 (22%)

0/9 (0%)*/**

2/9 (22%)

  1. Incidence = number of mice with tumors/total number of mice (n).
  2. Incidence, T ≥ 500 mm3 = number of mice with tumor volume ≥ 500 mm3/number of tumor-bearing mice.
  3. Multiplicity = number of tumors/total number of mice (n).
  4. Metastasis = number of mice with metastases/number of tumor-bearing mice.
  5. Liver Met = number of mice with liver metastases/number of tumor-bearing mice.
  6. Lung Met = number of mice with lung metastases/number of tumor-bearing mice.
  7. *P < 0.05 compared to placebo.
  8. ** P < 0.05 compared to gemcitabine.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us